Navigation Links
Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
Date:10/22/2008

rimarily by increased demand for Neulasta. Combined sales of Neulasta and NEUPOGEN in the U.S. were $856 million in the third quarter of 2008 versus $830 million in the third quarter of 2007, an increase of 3 percent primarily reflecting an increase in demand for Neulasta. This increase in demand was driven by an increase in the average net sales price, partially offset by a decline in units sold, which we believe was primarily due to customer stocking which occurred in the second quarter of 2008. Combined international sales increased 24 percent to $336 million in the third quarter of 2008 versus $270 million for the same quarter in the prior year. This growth reflects changes in foreign exchange which positively impacted third quarter 2008 combined international sales by approximately $33 million, as well as increased demand driven by the continued conversion from NEUPOGEN to Neulasta. Excluding the impact of foreign exchange, combined worldwide product sales increased 5 percent and international product sales increased 12 percent.

Sales of Enbrel(R) (etanercept) increased 9 percent in the third quarter to $893 million versus $821 million during the same period in 2007. Sales growth was driven by higher demand due to increases in both average net sales price and patients. ENBREL sales growth in the third quarter was affected by share declines in the U.S. versus the third quarter of 2007 due to increased competitive activity. However, sales growth continued in both rheumatology and dermatology, and ENBREL continues to maintain a leading position in both segments.

Worldwide sales of Sensipar(R) (cinacalcet) increased 32 percent to $161 million in the third quarter of 2008 versus $122 million during the third quarter of 2007. This growth was principally driven by demand, primarily due to segment penetration.

Vectibix(R) (panitumumab) sales for the third quarter were unchanged year over year at $41 million.

Operating Expense Analysis
'/>"/>

SOURCE Amgen
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related biology technology :

1. CNS Response Announces Fiscal Third Quarter 2007 Results
2. Avitar Reports Third Quarter Financial Results for Fiscal 2007
3. Martek to Announce Third Quarter 2007 Results on September 5, 2007
4. Third Security, LLC Hires Two New Managing Directors
5. Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
6. ThirdBiotech Networking Group Launches
7. BioMed Realty Trust Declares Third Quarter 2007 Common Stock and Preferred Stock Dividends
8. PPD Announces Third Quarter 2007 Earnings Release, Webcast and Conference Call
9. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
10. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
11. Americas Heartland Launches Third Season Highlighting Contributions of American Farmers and Ranchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  CorMedix Inc. (NYSE ... and commercializing therapeutic products for the prevention and ... receipt of notice on July 18, 2014 from ... has accepted the CorMedix plan to regain compliance ... a result, the NYSE-MKT is continuing the Company,s ...
(Date:7/24/2014)... Mich. , July 24, 2014  Neogen Corporation ... that future forecasts of its potential revenue from new ... call to investors and analysts on July 22, 2014, ... by analysts regarding this research. "It was ... questions about the potential of a new type of ...
(Date:7/24/2014)... The first part of the session on ... Human Studies” will cover comprehensive clinical support in early ... increasing R&D costs and declining industry success in getting ... knowledge collected in early Phase I/IIa study data to ... stage development. , Next, the presenters will examine steps ...
(Date:7/24/2014)... , July 24, 2014   Cypher ... today the appointment of Adam Simpson ... Genomics provides rapid and comprehensive annotation and interpretation ... clinical reporting. "Cypher,s technology has the ... healthcare by enhancing diagnostic accuracy, optimizing therapeutic approaches ...
Breaking Biology Technology:CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3Neogen comments on SenesTech 2Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 3
... in the sensitivity of weighing scales. Using the same ... functional nanotube radio, researchers with Berkeley Lab and the ... nanoelectromechanical system (NEMS) that can function as a scale ... atom of gold. , Alex Zettl, a physicist who ...
... SAN DIEGO, July 28 Ardea Biosciences, Inc.,(Nasdaq: ... be presented on RDEA806, the,Company,s novel investigational non-nucleoside ... virus (HIV) at,the 48th Annual ICAAC/IDSA 46th Annual ... Dr. Graeme Moyle, Director of HIV Research, Chelsea ...
... at IMAPS 2008 , ... Washington, D.C. (PRWEB) July ... proud to announce that Governor Carcieri and Dr Zolper have agreed ... on Microelectronics (IMAPS ,08) at the Providence, RI, Convention Center, November ...
Cached Biology Technology:Golden scales 2Golden scales 3Ardea to Present Data on Lead HIV Candidate, RDEA806, at ICAAC/IDSA Joint Meeting 2Ardea to Present Data on Lead HIV Candidate, RDEA806, at ICAAC/IDSA Joint Meeting 3Rhode Island Governor Donald L. Carcieri and Dr. John C. Zolper, Vice President, Raytheon Company to Speak at IMAPS 2008 2
(Date:7/24/2014)... cars ply silent freeways, solar panels blanket rooftops and ... from howling winds and from the blazing desert sun. ... technically and economically feasible to convert California,s all-purpose energy ... in Energy , the plan shows the way ... California that could create tens of thousands of jobs ...
(Date:7/24/2014)... research out of York University shows a surprisingly effective ... grass fungus: moose saliva (yes moose saliva). , ... saliva inhibits a grassendophyte mutualism" shows that moose and ... hosts a fungus called epichlo festucae that produces the ... toxicity. , "Plants have evolved defense mechanisms to protect ...
(Date:7/24/2014)... team of researchers has developed a new nanoscale agent ... method for assessing the function and properties of the ... diagnosis and treatment of gut diseases. , ... syndrome and inflammatory bowel disease all occur in the ... patients with diseases such as diabetes and Parkinson,s. ...
Breaking Biology News(10 mins):Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4Moose drool inhibits growth of toxic fungus: York U research 2New imaging agent provides better picture of the gut 2
... children and young adults for influenza is being seriously underestimated, ... historic vaccine programs have concentrated on the elderly and those ... computer modeling analysis was just published in the journal ... Health. The study suggests that children in school and young ...
... June 11, 2013 (BRONX, NY) Today, researchers ... Yeshiva University convened a one-day conference on Jewish genetics ... research. Such research could help scientists identify causes and ... common disorders afflicting the general population. The ...
... guarantee future support for international scientific collaborations funded by ... on a three year budgetary framework will extend the ... At an Intergovernmental Conference hosted by the European Commission ... governments that support the Human Frontier Science Program came ...
Cached Biology News:Flu vaccines aimed at younger populations could break annual transmission cycle 2Flu vaccines aimed at younger populations could break annual transmission cycle 3Albert Einstein College of Medicine hosts conference on Jewish genetic research 2
...
Request Info...
Streptomycin sulfate an aminoglycoside used for bacterial selection binds to the small ribosomal subunit and interferes with protein biosynthesis.21H39N7O12)2x3H2SO4Formula weight:...
Adducin beta (C-16)...
Biology Products: